Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab

被引：0
|
作者：
Rao, Vijay [1 ]
Pavlov, Andrey [2 ]
Klearman, Micki [1 ]
Musselman, David [3 ]
Giles, Jon T. [4 ]
Bathon, Joan M. [4 ]
Sattar, Naveed [5 ]
Lee, Janet S. [3 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Everest, Toronto, ON, Canada
[3] Roche, Nutley, NJ USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1642
引用
收藏
页码：S642 / S642
页数：1
相关论文
共 50 条
  • [1] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, Dave
    Giles, Jon
    Bathon, Joan
    Sattar, Naveed
    Lee, Janet
    RHEUMATOLOGY, 2012, 51 : 138 - 138
  • [2] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR (CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ)
    Rao, V. U.
    Pavlov, A.
    Klearman, M.
    Musselman, D.
    Giles, J. T.
    Bathon, J. M.
    Sattar, N.
    Lee, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 356 - 357
  • [3] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH THE INTERLEUKIN-6 RECEPTOR INHIBITOR TOCILIZUMAB
    Rao, Vijay Udyavar
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1648 - E1648
  • [4] Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
    Mal, Kheraj
    Kumar, Ratan
    Mansoor, Farah
    Kaur, Navneet
    Kumar, Anil
    Memon, Sidra
    Rizwan, Amber
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [5] An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
    Rao, Vijay U.
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon T.
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (02) : 372 - 380
  • [6] MAJOR ADVERSE CARDIOVASCULAR EVENTS: RISK FACTORS IN PATIENTS WITH RA TREATED WITH TOFACITINIB
    Charles-Schoeman, C.
    Valdez, H.
    Soma, K.
    Hwang, L.
    DeMasi, R.
    Boy, M.
    McInnes, I. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1034 - 1035
  • [7] Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
    Charles-Schoeman, Christina
    Valdez, Hernan
    Soma, Koshika
    Hwang, Lie-Ju
    DeMasi, Ryan
    Boy, Mary
    McInnes, Iain B.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [8] Risk of major adverse cardiovascular events in patients with rheumatoid arthritis using Janus Kinase inhibitors
    You, Seung-Hun
    Cho, Soo-Kyung
    Song, Yeo-Jin
    Sung, Yoon-Kyoung
    Jung, Sun-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 521 - 522
  • [9] Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
    Hirano, Toshitaka
    Sugiyama, Naonobu
    Hoshi, Masato
    Jo, Joo-Young
    Shin, Kichul
    Yamaoka, Kunihiro
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2526 - 2529
  • [10] Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept
    Generali, E.
    Carrara, G.
    Selmi, C.
    Verstappen, S.
    Zambon, A.
    Bortoluzzi, A.
    Silvagni, H.
    Scire, C. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (02) : 310 - 313
12345